Lytix Biopharma AS (OSL:LYTIX)

Lytix Biopharma AS Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 13, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	811	674	401	195	311	533
Market Cap Growth	133.96%	68.03%	106.12%	-37.37%	-41.63%	-
Enterprise Value	741	587	361	116	139	323
Last Close Price	10.55	9.83	5.85	4.84	7.72	13.69
PS Ratio	-	-	36.05	48.79	28.19	27.59
PB Ratio	13.14	10.92	3.72	3.80	2.30	2.81
P/TBV Ratio	13.14	10.92	3.72	3.80	2.30	2.81
EV/Sales Ratio	-	-	32.39	29.06	12.63	16.76
Debt / Equity Ratio	0.04	0.04	0.02	0.01	0.01	0.01
Net Debt / Equity Ratio	-1.14	-1.14	-1.19	-0.97	-1.06	-1.03
Net Debt / EBITDA Ratio	1.10	1.10	1.34	0.52	2.19	4.11
Net Debt / FCF Ratio	1.17	1.17	1.82	0.52	2.73	4.37
Asset Turnover	-	-	0.11	0.04	0.06	0.16
Quick Ratio	4.28	4.28	3.90	5.01	8.51	14.29
Current Ratio	4.28	4.28	3.91	5.06	8.55	14.33
Return on Equity (ROE)	-70.71%	-70.71%	-118.41%	-94.33%	-34.54%	-45.90%
Return on Assets (ROA)	-35.09%	-35.09%	-56.97%	-55.72%	-22.90%	-25.23%
Return on Capital Employed (ROCE)	-101.70%	-101.70%	-87.40%	-188.40%	-48.50%	-25.10%
Earnings Yield	-7.39%	-8.89%	-23.48%	-45.14%	-18.03%	-9.03%
FCF Yield	-	-8.87%	-17.53%	-49.31%	-16.98%	-8.37%
Buyback Yield / Dilution	-26.05%	-26.05%	-35.05%	-1.01%	-19.50%	-26.57%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.